The Wall Street Journal is reporting that Pfizer is nearing a deal to sell its nutritional business (which mainly makes baby formula) to Nestle for at least $9 billion. A sale of the business was widely expected, and is seen by many investors as a likely first step for the Brobdingnagian drug firm to spin off even more divisions, potentially eventually including its emerging business in medicines that have lost patent protection.
